As coronavirus continues to unfold, it is actively disrupting communities, clinicians, patients, the way we work, and how we engage to support stakeholders across the ecosystem. At the front and center, pharma and medtech companies can be found, supplying and rapidly scaling up vitally important medical products to support needy patients while also attracting widespread attention as the industry works to develop new therapeutics and vaccines for COVID-19.
These vaccines, diagnostics, and therapies could provide a crucial path to whatever next normal we find on the other side of COVID-19. Simultaneously, what McKinsey calls the product and clinical development “engine” has experienced profound disruption as lab capacity is reduced and colleagues adjust to remote work environments. Clinical trials are also being severely affected, with disruptions in keeping existing patients on therapies and new enrollment.
How can the life sciences industry meet these challenges head-on while focusing on the future?
Download our ebook, "Shifting to the Next Normal in Life Science: Care Driven By Innovation" for the answer!
Hi. Need help?